Oddo BHF Asset Management Sas Takes $1.57 Million Position in Kenvue Inc. (NYSE:KVUE)

Oddo BHF Asset Management Sas bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 67,884 shares of the company’s stock, valued at approximately $1,570,000.

A number of other institutional investors have also bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC bought a new position in shares of Kenvue during the 3rd quarter worth about $35,000. Deseret Mutual Benefit Administrators grew its stake in shares of Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after buying an additional 651 shares during the period. Studio Investment Management LLC raised its stake in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares during the period. Finally, Brooklyn Investment Group bought a new position in Kenvue in the third quarter worth approximately $71,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KVUE. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $24.00 in a research report on Thursday. Piper Sandler raised their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Trading Down 0.5 %

Shares of Kenvue stock opened at $22.21 on Friday. The firm has a market cap of $42.58 billion, a PE ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a fifty day moving average price of $22.95 and a 200-day moving average price of $21.17.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the previous year, the company earned $0.31 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. Equities research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.